Immune responses to tuberculosis in developing countries: implications for new vaccines

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a critical global health issue, particularly in developing countries, causing millions of deaths annually.
• The existing Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine demonstrates limited efficacy in these regions.
• Progressive TB is linked to a detrimental shift from protective T helper 1 (T(H)1) cell responses to immunopathological reactions.

Purpose of the Study:

• To analyze the immunological basis for the failure of current TB vaccines in developing countries.
• To propose a new strategy for TB vaccine development focused on modulating immune responses.

Main Methods:

• Review and discussion of existing immunological data related to TB pathogenesis and vaccine responses.
• Analysis of T helper 1 (T(H)1) cell response dynamics in the context of TB infection.

Main Results:

• Evidence suggests that the failure of TB vaccines is not due to insufficient T(H)1-cell responses.
• Instead, an overactive tendency to switch towards immunopathological responses contributes to disease progression.
• The context and regulation of T(H)1-cell activity are critical, not merely its magnitude.

Conclusions:

• A successful TB vaccine must inhibit the development of immunopathology.
• Future vaccine strategies should prioritize controlling the detrimental aspects of the immune response over simply enhancing T(H)1 activity.